



Adrenocortical Carcinoma: From Pathophysiology to Current and Emerging Therapeutic Approaches

Guest Editor:

Dr. Chitra Subramanian

Department of Surgery,
University of Michigan, Ann
Arbor, MI, USA

Deadline for manuscript
submissions:

closed (30 April 2021)

Message from the Guest Editor

Dear Colleagues,

Adrenocortical carcinoma (ACC) developing from the adrenal gland is a rare endocrine malignancy with a poor prognosis. Currently, surgery remains the first line of treatment. Adjuvant therapy with mitotane either alone or in combination with chemotherapy is the standard of care treatment for ACC. Recently, novel pathways that can be targets in ACC, such as insulin growth factor 2 (IGF2), beta-catenin pathway, and other pathways, have been identified. This resulted in several drugs targeting these pathways that have entered clinical trials. Despite advances in the development of novel treatment methods, ACC still has a dismal prognosis. Currently, immunotherapy has emerged as an important therapeutic option for several cancer models. However, the role of immunotherapy is not clear. Novel targets and treatments that can benefit ACC patients are still emerging. Therefore, the focus of this Special Issue will be on how the pathophysiology of ACC development drives the current as well as novel emerging therapies that can be of greater benefit to ACC patients.

Dr. Chitra Subramanian

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)